Series F round brings in $14mm for SynCardia Systems
Cardiovascular device developer SynCardia Systems Inc. raised $14mm through what is believed to be its Series F venture round. Returning shareholder Athyrium Capital Management invested $4mm and SWK Holding provided the remainder. The money will be used to continue developing and launch a smaller version (50cc vs. 70cc) of the SynCardia Total Artificial Heart, the first and only FDA- and Health Canada-approved and CE-Marked total artificial heart. Some funds will also be used to make the Freedom portable driver (which powers the SynCardia systems) available and to use SynCardia’s technology for destination therapy. Wedbush PacGrow Life Sciences was the placement agent.
- Medical Devices
- Implantable Devices
- Venture Financing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.